MediWound (NASDAQ:MDWD) PT Set at $31.00 by HC Wainwright

HC Wainwright set a $31.00 target price on MediWound (NASDAQ:MDWD) in a report issued on Thursday, MarketBeat.com reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on MDWD. Craig Hallum started coverage on MediWound in a research note on Friday, February 28th. They set a “buy” rating and a $39.00 target price for the company. Wall Street Zen raised shares of MediWound to a “sell” rating in a report on Friday, March 21st. Finally, Alliance Global Partners initiated coverage on shares of MediWound in a report on Friday, May 2nd. They set a “buy” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.25.

MediWound Stock Performance

MDWD opened at $20.37 on Thursday. The company has a fifty day moving average of $17.46 and a two-hundred day moving average of $17.62. The stock has a market capitalization of $220.16 million, a price-to-earnings ratio of -7.02 and a beta of 0.30. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00.

MediWound (NASDAQ:MDWD) last posted its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.58. The firm had revenue of $3.96 million for the quarter, compared to analysts’ expectations of $5.20 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the firm earned ($1.05) EPS. On average, equities research analysts forecast that MediWound will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On MediWound

Hedge funds and other institutional investors have recently made changes to their positions in the company. Yelin Lapidot Holdings Management Ltd. increased its position in shares of MediWound by 13.4% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after purchasing an additional 100,618 shares in the last quarter. Northern Trust Corp boosted its stake in MediWound by 94.6% during the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after purchasing an additional 70,367 shares during the last quarter. Essex Investment Management Co. LLC grew its holdings in shares of MediWound by 30.7% during the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock worth $2,651,000 after buying an additional 35,012 shares in the last quarter. MGO One Seven LLC acquired a new stake in shares of MediWound in the fourth quarter valued at about $216,000. Finally, Silverberg Bernstein Capital Management LLC lifted its stake in shares of MediWound by 13.1% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company’s stock worth $1,613,000 after buying an additional 12,060 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.